We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Hereditary Breast Cancer Tests Double Detection Rate

By LabMedica International staff writers
Posted on 23 May 2018
Germline genetic testing in patients newly diagnosed with cancer has the potential to reduce disease burden through secondary prevention and targeted therapies. More...
There is a prerequisite to understand how genetic testing is being integrated into practice for patients newly diagnosed with cancer and the impact of results on treatment decisions.

As clinical whole-genome sequencing becomes increasingly feasible, it is crucial to understand the implications of expanded genetic testing on practice and patient experiences. Yet virtually nothing is known about the uptake, results, or consequences of multiple-gene sequencing in community practice.

Multi-institutional scientists led by Stanford University (Stanford, CA, USA) surveyed a population-based retrospective cohort study of 5,080 patients with breast cancer diagnosed from January 2013 to December 2015 and accrued from Surveillance, Epidemiology, and End Results (SEER) registries across Georgia and in Los Angeles, California and the response rate was 70%. The patients were racially diverse group that included 51% white, 18% black, 19% Hispanic, 9% Asian, and 2.5% unknown-ethnicity patients.

Testing was performed by four laboratories: Ambry Genetics, GeneDx, Invitae and Myriad Genetics and the results were merged with the SEER clinical data and survey responses. Testing switched from BRCA1/2-only to multi-gene panels: at the beginning, multi-gene sequencing accounted for 25.6 %, and BRCA1/2-testing for 74.4% of tests, which switched to 66.5% for multi-gene panels and 33.5% for BRCA1/2-testing at the end.

Pathogenic variants for which guidelines advise a change in care were detected twice as often in patients who had multi-gene sequencing than in those who only had BRCA1 and BRCA2 analyzed. Those variants occurred in a variety of genes, including CHEK2, ATM, PALB2, APC, BRIP1, PMS2, and RAD51C. However, variants of uncertain significance (VUS) were also ten times more frequent in multi-gene-testers; about 30% received one, than in BRCA1/2-only testers, who only had a 3% VUS rate. This was especially true for certain groups: 51% of Asian patients tested with a multi-gene panel, for example, had a VUS, and 45% of black patients.

The authors concluded that multiple-gene sequencing rapidly replaced BRCA1/2-only testing for patients with breast cancer in the community and enabled two-fold higher detection of clinically relevant pathogenic variants without an associated increase in prophylactic mastectomy. However, important targets for improvement in the clinical utility of multiple-gene sequencing include postsurgical delay and racial/ethnic disparity in variants of uncertain significance. The study was published on May 10, 2018, in the journal JAMA Oncology.

Related Links:
Stanford University


Gold Member
Troponin T QC
Troponin T Quality Control
Serological Pipet Controller
PIPETBOY GENIUS
New
Drug Test Kit
DrugCheck 3000
New
Modular Hemostasis Automation Solution
CN Track
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.